Belantamab Mafodotin + Other Drugs for Amyloidosis

(ALANIS Trial)

This trial tests a combination of drugs, including belantamab mafodotin (an experimental treatment), to determine their effectiveness and safety in treating AL amyloidosis, a condition where abnormal proteins accumulate in organs. Researchers aim to discover if this treatment benefits those newly diagnosed with the disease. Individuals with AL amyloidosis who are not eligible for high-dose chemotherapy with stem cell transplantation might be suitable candidates for this study. Participants will receive varying doses to identify the optimal treatment amount. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Research has shown that belantamab mafodotin has been tested in people with relapsed or hard-to-treat light-chain amyloidosis. These studies found that most participants tolerated the treatment well, though some experienced side effects. The most common side effects included eye problems, such as blurry vision and dry eyes.

The FDA has also approved belantamab mafodotin for use with two other drugs, bortezomib and dexamethasone, in treating multiple myeloma. This approval indicates that the safety of this treatment combination is well-established.

In trials, combining belantamab mafodotin with bortezomib and dexamethasone helped patients live longer, suggesting that the benefits might outweigh the risks for some individuals. Cyclophosphamide, another drug in the study, is frequently used in cancer treatment and is generally considered safe.

Researchers are excited about Belantamab Mafodotin for amyloidosis because it offers a unique approach by targeting BCMA (B-cell maturation antigen), which is not the focus of most standard treatments. Standard treatments like CyBorD (Cyclophosphamide, Bortezomib, and Dexamethasone) primarily work by targeting and killing rapidly dividing cells. In contrast, Belantamab Mafodotin is an antibody-drug conjugate that precisely delivers its cytotoxic payload to BCMA-expressing cells, potentially leading to more effective outcomes with fewer side effects. This targeted mechanism could mean better results and improved quality of life for patients with amyloidosis.

Research has shown that belantamab mafodotin may help treat AL amyloidosis. In earlier studies, this drug improved patients' conditions with a 40% success rate. In this trial, participants will receive belantamab mafodotin combined with other drugs, such as bortezomib and cyclophosphamide. Bortezomib has already proven effective for AL amyloidosis, and cyclophosphamide is a well-known chemotherapy drug. Together, these treatments might effectively manage the condition by reducing harmful protein deposits.⁶⁷⁸⁹¹⁰